The New York Entrepreneur

[stock-market-ticker symbols="AAPL;MSFT;GOOG;HPQ;^SPX;^DJI;LSE:BAG" stockExchange="NYSENasdaq" width="100%" palette="financial-dark"]

Menu

Home
Wall Street Today
Economy
- Market Analysis
Newsletters and Research
Cryptocurrency
Business
Finance
Market Analysis
Money

Home
2024
July
Guardant Health’s stock up after FDA approves its blood test for colon-cancer screening

Guardant Health’s stock up after FDA approves its blood test for colon-cancer screening

Share

Read Time:7 Second

It’s the first such blood test to receive regulatory approval in the U.S. and the first that meets the requirements for Medicare coverage.

About Post Author

Happy

0 0 %

Sad

0 0 %

Excited

0 0 %

Sleepy

0 0 %

Angry

0 0 %

Surprise

0 0 %

0

0

Previous post U.S. IPO market’s $23.2 billion in year-to-date proceeds exceeds the $19.4 billion raised for all of 2023

Next post McDonald’s is falling short, needs to win over low-income consumers, key exec tells operators in memo

More Stories

With meme stocks in a lull, here’s where retail investors may turn their attention next

The dynamics that fueled the meme-stock frenzy have not gone away, according to a recent study.

September 20, 2024

Micron’s stock sentiment is weak. Here’s what could flip the script.

Micron shares have shed most of their 2024 gains, but memory pricing could improve in the coming months, Citi says.

September 20, 2024

Shohei Ohtani, the first to ever achieve 50/50, is the 352nd highest-paid player in MLB this season

That’s in part because most of his $700 million contract is deferred. Still, his stats this season are worth over...

September 20, 2024

Why Constellation Energy and Vistra shares are building on massive gains

Constellation has a new nuclear-power deal with Microsoft. Both Constellation and Vistra shares have more than doubled this year on...

September 20, 2024

Why Fed bets were so out of whack: Waller explains what put him ‘over the edge’ for a jumbo rate cut

Inflation might actually fall too far, Fed governor says.

September 20, 2024

FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also ‘on notice’

Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.

September 20, 2024

Post navigation

Previous post:U.S. IPO market’s $23.2 billion in year-to-date proceeds exceeds the $19.4 billion raised for all of 2023

Next post:McDonald’s is falling short, needs to win over low-income consumers, key exec tells operators in memo

Search for:

Recent Posts

With meme stocks in a lull, here’s where retail investors may turn their attention next
Micron’s stock sentiment is weak. Here’s what could flip the script.
Shohei Ohtani, the first to ever achieve 50/50, is the 352nd highest-paid player in MLB this season
Why Constellation Energy and Vistra shares are building on massive gains
Why Fed bets were so out of whack: Waller explains what put him ‘over the edge’ for a jumbo rate cut

Wall Street Today

Wall Street Today

Stocks to Watch

Other

Newsletters & Research

Policy & Regulation

Business

© 2022 The New York Entrepreneur. All Rights Reserved.